Fananapazir L, Epstein ND.Prevalence of
hypertrophic cardiomyopathy and limitations of screening methods. Circulation.1995;92:700-704.
Wigle ED, Rakowski H, Kimball BP, Williams WG.Hypertrophic cardiomyopathy: clinical spectrum and treatment. Circulation.1995;92:1680-1692.
Fananapazir L, McAreavey D, Epstein ND.Hypertrophic
cardiomyopathy.In: Zipes D, Jalife J, eds.
Cardiac Electrophysiology, From Cell to
BedsidePhiladelphia: WB Saunders Co; 1995:769-779.
Fananapazir L, McAreavey D.Hypertrophic cardiomyopathy:
evaluation and treatment of patients at high risk for sudden death. Pacing Clin Electrophysiol.1997;20:478-501.
Geisterfer-Lowrance AAT, Kass S, Tanigawa G.
et al. A
molecular basis for familial hypertrophic cardiomyopathy: a beta
cardiac myosin heavy chain gene missense mutation. Cell.1990;62:999-1006.
Thierfelder L, Watkins H, MacRae C.
et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial
hypertrophic cardiomyopathy: a disease of the sarcomere. Cell.1994;77:701-712.
Bonne G, Carrier L, Bercovici J.
et al. Cardiac myosin
binding protein-C splice receptor mutation is associated with familial
hypertrophic cardiomyopathy. Nat Genet.1995;11:438-440.
Poetter K, Jiang He, Hassanzadeh S.
et al. Mutations in
either the essential or regulatory light chains of myosin are
associated with a rare myopathy in human heart and skeletal muscle. Nat Genet.1996;13:63-69.
Kimura A, Harada H, Park JE.
et al. Mutations in the
cardiac troponin I gene associated with hypertrophic cardiomyopathy. Nat Genet.1997;16:379-382.
MacRae CA, Ghaisas N, Kass S.
et al. Familial
hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. J Clin Invest.1995;96:1216-1220.
Bonne G, Carrier L, Richard P, Hainque B, Schwartz K.Familial hypertrophic cardiomyopathy: from mutations to functional
defects. Circ Res.1998;83:580-593.
Epstein ND, Cohn GM, Cyran F, Fananapazir L.Differences in clinical expression of hypertrophic cardiomyopathy
associated with two distinct mutations in the β-myosin heavy chain
gene: a 908Leu-Val mutation and a 403Arg-Gln mutation. Circulation.1992;86:345-352.
Fananapazir L, Epstein ND.Genotype-phenotype
correlations in hypertrophic cardiomyopathy: insights provided by
comparisons of kindreds with distinct and identical β-myosin heavy
chain gene mutations. Circulation.1994;89:22-32.
Rayment I, Holden HM, Sellers J, Fananapazir L, Epstein ND.Structural interpretation of the mutations in the β-cardiac
myosin that have been implicated in familial hypertrophic
cardiomyopathy. Proc Natl Acad Sci U S A.1995;92:3864-3868.
Cuda G, Fananapazir L, Zhu WS, Sellers JR, Epstein ND.Skeletal muscle expression and abnormal function of β-myosin in
hypertrophic cardiomyopathy. J Clin Invest.1993;91:2861-2865.
Lankford EB, Sweeney HL, Epstein ND, Fananapazir L.Abnormal contractile properties of muscle fibers expressing mutations
in β-myosin in patients with hypertrophic cardiomyopathy. J Clin
Invest.1995;95:1409-1414.
Cuda G, Fananapazir L, Epstein ND, Sellers JR.The in
vitro motility activity of β-cardiac myosin depends on the nature of
the β-myosin heavy-chain gene mutation in hypertrophic
cardiomyopathy. J Muscle Res Cell Motil.1997;18:1-9.
Fananapazir L, Dalakas MC, Cyran F, Cohn G, Epstein ND.Missense mutations in the β-myosin heavy-chain gene cause central
core disease in hypertrophic cardiomyopathy. Proc Natl Acad Sci U
S A.1993:90:3993-3997.
Kramer CM, Reichek N, Ferrari VA, Theobald T, Dawson J, Axel L.Regional heterogeneity of function in hypertrophic
cardiomyopathy. Circulation.1994;90:186-194.
Rigat B, Hubert C, Allenc-Gellas F, Cambien F, Corvol P, Soubrier F.An insertion/deletion polymorphism in the angiotensin
I-converting enzyme gene accounting for half the variance of serum
enzyme levels. J Clin Invest.1990;86:1343-1346.
Lechin M, Yu QT, Workman R, Greve G, Roberts R.Angiotensin-converting enzyme polymorphism in hypertrophic
cardiomyopathy [abstract]. Circulation.1994;90(suppl
I):I-174.
Fananapazir L, Masters S, Winkler J.
et al. ACE gene
polymorphism and ACE levels as determinants of left ventricular
hypertrophy in hypertrophic cardiomyopathy caused by β-myosin
heavy-chain mutations [abstract]. Circulation.1996;94:I-110.
Molkentin JD, Lu J, Antos C.
et al. A
calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell.1998;93:215-228.
Palmiter KA, Solaro RJ.Molecular mechanisms regulating
the myofilament response to Ca2+: implications of mutations
causal for familial hypertrophic cardiomyopathy. Basic Res
Cardiol.1997;92:63-74.
Sussman MA, Lim HW, Gude N.
et al. Prevention of
cardiac hypertrophy in mice by calcineurin inhibition. Science.1998;281:1690-1693.
Fananapazir L, Chang AC, Epstein SE, McAreavey D.Prognostic determinants in hypertrophic cardiomyopathy: prospective
evaluation of a therapeutic strategy based on clinical, Holter,
hemodynamic, and electrophysiologic findings. Circulation.1992;86:730-740.
Fananapazir L, Leon MB, Cannon RO, Bonow RO, Winkler J, Epstein SE.Sudden death during empiric amiodarone therapy in
symptomatic patients with hypertrophic cardiomyopathy. Am J
Cardiol.1991;67:169-174.
O'Donoghue S, Platia E, Mispireta L.
et al. Safety of
defibrillator implantation in patients with hypertrophic cardiomyopathy
[abstract]. J Am Coll Cardiol.1994;23:11.
Zhu DW, Sun H, Hill R, Roberts R.The value of
electrophysiology study and prophylactic implantation of cardioverter
defibrillator in patients with hypertrophic cardiomyopathy. Pacing
Clin Electrophysiol.1998;21(1 pt 2):299-302.
Dilsizian V, Bonow RO, Epstein SE, Fananapazir L.Myocardial ischemia detected by Thallium scintigraphy is frequently
related to cardiac arrest and syncope in young patients with
hypertrophic cardiomyopathy. J Am Coll Cardiol.1993;22:796-804.
Fananapazir L, McAreavey D.Therapeutic options in
patients with obstructive HCM and severe drug-refractory symptoms. J Am Coll Cardiol.1998;31:259-264.
Fananapazir L, Atiga W, Tripodi D, Steele S, McAreavey D.Obstructive hypertrophic cardiomyopathy: therapeutic
options.In: Barold SS, Mugica J, eds. Advances in Cardiac Pacing:
Goals for the 21st CenturyVol 4. Armonk, NY: Futurea Publishing
Co; 1998:35-48.
Sigwart U.Non-surgical myocardial reduction for
hypertrophic obstructive cardiomyopathy. Lancet.1995;346:211-214.
Geitzen F, Leuner C, Gerenkamp T, Kuhn H.Transcoronary ablation of septal hypertrophy: a new catheter
interventional therapy of hypertrophic obstructive cardiomyopathy. Circulation.1996;94(suppl 1):I84.
Seggewiss H, Gleichmann U, Faber L.
et al. Percutaneous
transluminal myocardial ablation (PTSMA) in hypertrophic obstructive
cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol.1998;31:252-258.
Lakkis NM, Nagueh SF, Kleiman NS.
et al. Echocardiographic-guided ethanol septal reduction for hypertrophic
obstructive cardiomyopathy. Circulation.1998;98:1750-1755.
Faber L, Seggewiss H, Gleichmann U.Percutaneous
transluminal septal myocardial ablation in hypertrophic obstructive
cardiomyopathy. Circulation.1998;98:2515-2421.